ReviewCurrent hematologic malignancy reports2024
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.
Review in Current hematologic malignancy reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Dermatologic Adverse Events Associated with T-Cell Engager Therapy.American journal of clinical dermatology · 2026Review
- Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions.Journal of immunotherapy and precision oncology · 2026Review
- Advances in the pathophysiology and treatment of anaemia in multiple myeloma.Current opinion in hematology · 2026Review
- Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology · 2026Review
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
- Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care.Frontiers in oncology · 2026Review
- Article
- Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma.Blood cancer journal · 2025Article
- Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations.Current oncology (Toronto, Ont.) · 2025Review
- T-Cell Engagers In Multiple Myeloma: A Clinical Review.Blood and lymphatic cancer : targets and therapy · 2025Review
- The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma.Frontiers in medicine · 2025Article
- Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies.Frontiers in immunology · 2025Article
- A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma.Frontiers in oncology · 2025Article
- Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma.Pharmaceutical patent analyst · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of the toxicities associated with newly approved T cell-engaging bispecific antibodies and those which may be approved in the near future. RECENT
findingsNumerous trials have shown that bispecific antibodies can be both effective and tolerable when adverse events are properly managed. Cytokine release syndrome and increased infections are observed across all bispecific antibodies. Additional adverse events are target-specific, such as the more severe hypogammaglobulinemia and infections of BCMA bispecific antibodies and the dysgeusia, nail dystrophy, and skin changes of GPRC5D bispecific antibodies. Bispecific antibodies will surely become a mainstay of multiple myeloma therapy given their efficacy and accessibility. Their unique toxicities must be carefully considered and managed to ensure they are utilized safely.
Indexed as
Identifiers
39145912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.